Patient Advocacy Cure HHT is a dedicated patient advocacy organization focused on hereditary hemorrhagic telangiectasia (HHT), with ongoing initiatives to seed research, standardize treatments, and build global treatment access. This presents a sales opportunity to align with their research funding programs, educational offerings, and clinical network expansion.

Registry & Data The organization is actively building an HHT patient registry to identify effective treatments, which signals openness to data collaboration, research partnerships, and technology integrations that improve data capture, analytics, and reporting tools.

Website & Tech Recent activity includes calls for a comprehensive website rebuild and ongoing use of common enterprise tools (Salesforce, Microsoft 365) and web technologies. This suggests opportunities for digital transformation services, CRM optimization, patient access portals, and secure data workflows.

Strategic Partnerships Recent partnerships and collaborations with industry players (for example Diagonal Therapeutics) indicate a favorable stance toward biotech and clinical research alliances, opening doors for sponsored research, co-development opportunities, and patient-centric study initiatives.

Funding & Growth With revenue in the 50–100 million range and a history of fundraising, grants, and outreach (including government funding advocacy), Cure HHT may be interested in services that support grant management, donor engagement, and scalable program administration to sustain and expand impact.